REVIEW PAPER
Fosfomycin as an alternative therapeutic option for treatment of infections caused by multi-resistant Gram-negative bacteria
 
More details
Hide details
1
Department of Pharmaceutical Microbiology with Laboratory for Microbiological Diagnostics, Medical University of Lublin, Poland
2
Department of Pharmaceutical Microbiology with Laboratory for Microbiological Diagnostics, Medical University of Lublin, Poland
CORRESPONDING AUTHOR
Sylwia Andrzejczuk   

Department of Pharmaceutical Microbiology with Laboratory for Microbiological Diagnostics, Medical University of Lublin, 20-059 Lublin, Poland
 
J Pre Clin Clin Res. 2014;8(2):51–54
KEYWORDS
ABSTRACT
The problem of significantly reduced drug use concerns particularly the infections caused by multi-resistant pathogens, especially Gram-negative bacteria. In this regard, interest is increasing in the known for nearly 50 years, but now frequently forgotten antibiotic – fosfomycin. Fosfomycin possesses high effectiveness for multidrug-resistant bacteria, comprising of extended-spectrum β-lactamases (ESBL), Klebsiella pneumoniae carbapenemases (KPC); commonly, the pandrug-resistant (PDR) and the extensively drug-resistant (XDR) strains, especially from Enterobacteriaceae family. Because of facilitated distribution into inflamed tissues and a very broad range of in vitro bactericidal activity, fosfomycin may have various applications in the treatment of many kinds of bacterial infections, including acute uncomplicated infections of the urinary bladder or complicated urinary tract infections, urinary tract sepsis, pyelonephritis, cystitis, prostatitis and chronic lung infections in patients with cystic fibrosis, the great majority caused by multi-resistant Gram-negative bacteria, and in the therapy eradicating multidrug-resistant Helicobacter pylori. Fosfomycin may limit the toxicity of other antibiotics and play a protective role in the process of bacterial resistance development during the therapy. Combinations of different antimicrobials enable the use of forgotten antibiotics in commonly occurring infections, although they are still completely incurable.
 
REFERENCES (32)
1.
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012; 18(3): 268–281.
 
2.
Bergen PJ, Landersdorfer CB, Lee HJ, Li J, Nation RL. ‘Old’ antibiotics for emerging multidrug-resistant bacteria. Curr Opin Infect Dis. 2012; 25(6): 626–633.
 
3.
Hendlin D, Stapley EO, Jackson M, Wallick H, Miller AK, Wolf FJ, Miller TW, Chaiet L, Kahan FM, Foltz EL, Woodruff HB, Mata JM, Hernandez S, Mochales S. Phosphonomycin, a new antibiotic produced by strains of Streptomyces. Science. 1969; 166: 122–123.
 
4.
Raz R. Fosfomycin: an old-new antibiotic. Clin Microbiol Infect. 2012; 18: 4–7.
 
5.
Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011; 15(11): 732–739.
 
6.
Mirakhur A, Gallagher MJ, Ledson MJ, Hart CA, Walshaw MJ. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Cyst Fibros. 2003; 2(1): 19–24.
 
7.
Jóźwik M. Skuteczność lecznicza preparatu MONURAL® w zwalczaniu zakażeń układu moczowego u kobiet. Gin Prakt. 2005; 87(6): 24–28 (in Polish).
 
8.
Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010; 10(1): 43–50.
 
9.
Gupta V, Rani H, Singla N, Kaistha N, Chander J. Determination of extended-spectrum β-lactamases and AmpC production in uropathogenic isolates of Escherichia coli and susceptibility to fosfomycin. J Lab Physicians. 2013; 5(2): 90–93.
 
10.
Oteo J, Bautista V, Lara N, Cuevas O, Arroyo M, Fernández S, Lázaro E, de Abajo FJ, Campos J. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum β-lactamase (ESBL)- producing Escherichia coli. J Antimicrob Chemother. 2010; 65(11): 2459–2463.
 
11.
Oteo J, Orden B, Bautista V, Cuevas O, Arroyo M, Martinez-Ruiz R, Perez-Vazquez M, Alcaraz M, Garcia-Cobos S, Campos J. CTX-M-15- producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemother. 2009; 64(4): 712–717.
 
12.
Lefort A, Chau F, Lepeule R, Dubée V, Kitzis MD, Dion S, Fantin B. Activity of fosfomycin alone or combined with cefoxitin in vitro and in vivo in a murine model of urinary tract infection due to Escherichia coli harbouring CTX-M-15-type extended-spectrum β-lactamase. Int J Antimicrob Agents. 2014; 43(4): 366–369.
 
13.
Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, Oikonomou A, Poulakou G, Roilides E, Giamarellou H. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents. 2014; 43(1): 52–59.
 
14.
Ho PL, Chan J, Lo WU, Lai EL, Cheung YY, Lau TC, Chow KH. Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary Escherichia coli isolates. J Med Microbiol. 2013; 62(11): 1707–1713.
 
15.
Tullio V, Cuffini AM, Banche G, Mandras N, Allizond V, Roana J, Giacchino F, Bonello F, Ungheri D, Carlone NA. Role of fosfomycin tromethamine in modulating non-specific defence mechanisms in chronic uremic patients towards ESBL-producing Escherichia coli. Int J Immunopathol Pharmacol. 2008; 21(1):153–160.
 
16.
Samonis G, Maraki S, Karageorgopoulos DE, Vouloumanou EK, Falagas ME. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis. 2012; 31(5): 695–701.
 
17.
Corvec S, Furustrand TU, Betrisey B, Borens O, Trampuz A. Activity of fosfomycin, tigecycline, colistin and gentamicin against extended spectrum beta-lactamase-producing E. coli in a foreign-body infection model. Antimicrob Agents Chemother. 2013; 57(3): 1421–1427.
 
18.
Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs. 2009; 69(14): 1879– 1901.
 
19.
Kastoris AC, Rafailidis PI, Vouloumanou EK, Gkegkes ID, Falagas ME. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. Eur J Clin Pharmacol. 2010; 66(4): 359–368.
 
20.
Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant Gram-negative organisms: extended-spectrum β-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae and multi-resistant Pseudomonas aeruginosa. Mayo Clin Proc. 2011; 86(3): 250–259.
 
21.
Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M, Moorehead L, Montgomery AB, Geller DE. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med. 2012; 185(2): 171–178.
 
22.
UpToDate: Fosfomycin Drug Information. 2011. Available at: http:// www.uptodate.com.contents.fosf... (accessed: 2014.07.12).
 
23.
Schito GC. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int J Antimicrob Agents. 2003; 22(Suppl 2): 79–83.
 
24.
Neuner EA, Sekeres J, Hall GS, van Duin D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemoter. 2012; 56(11): 5744–5748.
 
25.
The Office for Registration of Medical Products, Medical Devices and Biocidal Products. en.urpl.gov.pl.
 
26.
Gardiner BJ, Mahony AA, Ellis AG, Lawrentschuk N, Bolton DM, Zeglinski PT, Frauman AG, Grayson ML. Is fosfomycin a potential treatment alternative for multidrug-resistant Gram-negative prostatitis? Clin Infect Dis. 2014; 58(4): 101–105.
 
27.
Montgomery AB, Vallance S, Abuan T, Tservistas M, Davies A. A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow® Inline Nebulizer System in mechanically ventilated patients. J Aerosol Med Pulm Drug Deliv. 2014; 27(6): 441– 448.
 
28.
Boyanova L, Davidkov L, Gergova G, Kandilarov N, Evstatiev I, Panteleeva E, Mitov I. Helicobacter pylori susceptibility to fosfomycin, rifampin, and 5 usual antibiotics for H. pylori eradication. Diagn Microbiol Infect Dis. 2014; 79(3): 358–361.
 
29.
Barahona-Garrido J, Quiñonez NF, Cerda-Contreras E, Maria Sarti H, Téllez-Ávila FI. Fosfomycin-containing second-line treatment for Helicobacter pylori infection. Am J Gastroenterol. 2013;108(5): 858–859.
 
30.
Polskie Towarzystwo Walki z Mukowiscydozą [Polish Association for Mucoviscidosis Control] http://www.ptwm.org.pl/ (access: 2014.01.07) (in Polish).
 
31.
MacLeod DL, Barker LM, Sutherland JL, Moss SC, Gurgel JL, Kenney TF, Burns JL, Baker WR. Antibacterial activities of a fosfomycin/ tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother. 2009; 64(4): 829–836.
 
32.
Popovic M, Steinort D, Pillai S, Joukhadar C. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis. 2010; 29(2): 127–142.
 
eISSN:1898-7516
ISSN:1898-2395